Immuron Limited [NASDAQ: IMRN] has shared the potential antiviral benefits of IMM-124E in a mouse model and human clinical study in a contemporary statement. IMRN has been chasing the antiviral activities of IMM-124E and these recently proclaimed outcomes backing the ongoing R&D program. The research discoveries were recently circulated on the 1st of October 2021.
In the preclinical trial, mice were orally inoculated with HBC for 5 days and tested for the number of T cell clones releasing IFNγ in response to viral antigens of the swine flu, New Caledonia influenza, and cytomegalovirus. The stated data indicates that IMM124E improves antiviral immunity across the viral strains examined. A similar response was examined in the human study.
In the human trial, healthy participants were registered and got IMM-124E at a daily dose of 600 mg for four back-to-back days and 1200 mg for an additional day. Blood samples were gathered before and after IMM-124E therapy and analyzed for the number of T cell clones producing IFNγ in response to viral antigens of SARS-CoV-2 and Hepatitis B virus.
Furthermore, the preliminary clinical data shared has demonstrated that a similar consequence was witnessed in humans in augmenting antiviral responses against COVID-19 and Hepatitis B. While more detailed and comprehensive studies are necessary to further confirm the results, this is very positive research.
Additionally, IMRN also disclosed that it has submitted a Patent Cooperation Treaty (PCT) application to obtain patent protection internationally for IMM-124E which highlighted neutralizing activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.